Introduction {#sec1_1}
============

Choroidal neovascular membranes (CNV) can be associated with various inflammatory chorioretinal diseases, as the cytokines together with the vascular endothelial growth factor (VEGF) are implicated in the pathogenetic mechanisms leading to an impaired permeability and altered angiogenesis \[[@B1],[@B2]\]. It is assumed that CNV may occur in up to 25% of cases with serpiginous choroiditis and may be detected at the time of active choroiditis or in between the inflammatory episodes \[[@B3]\]. In a systemic immunosuppressive therapy for eye disease cohort study, 81 eyes (2%) had CNV at presentation among the 4,041 eyes of the 2,307 patients with posterior uveitis or panuveitis \[[@B4]\]. Of the 148 eyes with a diagnosis of serpiginous choroiditis, CNV was noted in 7 eyes (4.7%). The presence of CNV must be differentiated from the signs of active disease as the treatment options may differ. We hereby report a case of active serpiginous choroiditis with CNV and discuss our therapeutic approach.

Case Report {#sec1_2}
===========

A 42-year-old otherwise healthy woman with a visual loss of 2 months\' duration in OD in 2009 was examined by us. Her best-corrected visual acuity was counting fingers (CF) at 1 m in OD and 20/20 in OS. No sign of anterior chamber and vitreous inflammation was present. On fundus evaluation, there were chorioretinal scars surrounding the optic disc in a serpentine-like fashion OU, together with a subfoveal grayish lesion and subretinal hemorrhage in OD (fig. [1](#F1){ref-type="fig"}). Our diagnosis was inactive bilateral serpiginous choroiditis and subfoveal classic CNV in OD. A single session of photodynamic therapy and 3 subsequent intravitreal ranibizumab injections were administered in a time span of 9 months without any visual improvement. Four years later, at the age of 46, she was once again examined by us; this time for metamorphopsia and mild visual loss of 2 weeks\' duration in OS. Visual acuity was CF at 1 m in OD and 20/30 in OS. While slit-lamp examination was normal in OD, there were ++ cells in the left vitreous. On fundus evaluation, there was a large macular scar and extensive chorioretinal scarring surrounding the optic disc in OD (fig. [2a, b](#F2){ref-type="fig"}). In OS, peripapillary scarring with active-looking creamy borders and a grayish lesion with a hemorrhagic rim in the papillomacular bundle were noted (fig. [2c](#F2){ref-type="fig"}). With the help of fluorescein angiography and optical coherence tomography (fig. [2d-f](#F2){ref-type="fig"}), we reached a diagnosis of extrafoveal classic-type CNV in association with active serpiginous choroiditis in OS. In order to avoid systemic steroids, a single intravitreal dexamethasone implant was injected simultaneously with ranibizumab. The risks and benefits of the simultaneous intravitreal injection of the 2 drugs were explained to the patient, and an informed consent was obtained. At the same time, oral mycophenolic acid 2 × 720 mg was commenced. A week later, visual acuity was improved to 20/25, and optical coherence tomography showed that intraretinal and subfoveal fluid had almost totally disappeared. During the follow-up of 22 months, no further injection was required, and no injection-related complication occurred. Oral cyclosporine 3 × 100 mg was added to the systemic therapy due to the persistent activity of the inflammation 2 months later. At the last visit, she was still on the same systemic regimen. Visual acuities were CF in OD and 20/25 in OS, and the left fundus was relatively stabilized (fig. [3](#F3){ref-type="fig"}).

Discussion {#sec1_3}
==========

A thorough control of underlying inflammation with the help of systemic steroids and/or immunosuppressives should be considered in eyes with active serpiginous choroiditis associated with CNV. However, local targeted therapy is often administered to treat the coexistent CNV to obtain a better anatomical and visual outcome.

In earlier days, argon laser photocoagulation was the preferred method for the treatment of extrafoveal CNV \[[@B5],[@B6],[@B7]\] and photodynamic treatment mostly for the juxtafoveal and subfoveal CNV in serpiginous choroiditis \[[@B8],[@B9],[@B10]\]. More recently, intravitreal anti-VEGFs were evaluated in eyes with serpiginous choroiditis and CNV \[[@B11],[@B12],[@B13],[@B14],[@B15]\]. Patients were followed up for 36 months to assess the efficacy of intravitreal bevacizumab administration in a retrospective multicenter consecutive case series comprised of 81 patients with inflammatory ocular neovascularization refractory to standard therapy \[[@B12]\]. Ten of those eyes had serpiginous choroiditis and 50% of the CNV was subfoveal. Half of these patients have already been on systemic steroids and/or immunosuppressives. The mean number of bevacizumab injections in those eyes was 2.5. On the other hand, eyes with multifocal choroiditis and CNV required a mean of 6.3 injections, eyes with ocular histoplasmosis a mean of 3.9, and eyes with punctate inner choroidopathy a mean of 3.4 injections. Parodi et al. \[[@B15]\] reported their results of intravitreal bevacizumab administration in 7 eyes of 7 patients with CNV and serpiginous choroiditis who were followed up for a year with monthly follow-ups. All patients had also been on various systemic therapies. One eye required 5 bevacizumab injections, and the remaining eyes received only a single injection. Only 1 eye experienced a visual loss of 2 lines or more. The remaining 6 eyes either experienced visual gain, or the vision remained stable. Song and Roh \[[@B11]\] described a 44-year-old woman with inactive serpiginous choroiditis and juxtafoveal CNV. Two ranibizumab injections 2 months apart were sufficient to obtain a stable lesion without any concurrent systemic therapy. The patient was followed up for 6 more months after the second injection, and the visual acuity improved to 20/20 from the initial level of 20/40. In a group of 16 eyes of 15 consecutive patients with an inflammatory type of CNV, eyes were treated with repeated intravitreal ranibizumab injections \[[@B13]\]. Only 2 of those patients had an inactive type of serpiginous choroiditis. Both patients received 2 ranibizumab injections. In 1 eye, visual acuity remained stable, and the other eye experienced a 15-letter improvement. The follow-up was 52 and 64 weeks, respectively. Balaskas et al. \[[@B14]\] reported a 55-year-old man with an already established diagnosis of inactive serpiginous choroiditis with an extrafoveal classic-type CNV. Following a 3-daily intravenous infusion of prednisolone 1 g, 2 sessions of argon laser photocoagulation and then 2 photodynamic therapy treatments were performed. Upon worsening, 8 consecutive ranibizumab injections were given. The final visual acuity was 20/20.

In the present case with active serpiginous choroiditis and extrafoveal CNV, we preferred to intravitreally inject both ranibizumab and the dexamethasone implant simultaneously. The rationale for the dexamethasone implant was to suppress the active inflammation until the effect of the newly started immunosuppressive agent was commenced. There were some previous reports on the intravitreal steroid administration for the control of active inflammation in serpiginous choroiditis \[[@B16],[@B17],[@B18]\]. Wadhwa et al. \[[@B17]\] injected intravitreal triamcinolone acetonide in 8 eyes of 8 patients with active unilateral serpiginous choroiditis. They reported that remission was induced rapidly, and the visual acuities were either stabilized or improved after the follow-up of 6 months. Seth and Gaudio \[[@B18]\] placed a fluocinolone implant after the observation of a good disease control with a single intravitreal triamcinolone acetonide administration, and the visual outcome was satisfactory during a follow-up of 14 months.

As there are no randomized studies for the treatment of CNV in association with inflammatory diseases, such as the ones associated with age-related macular degeneration and pathologic myopia, a tailored therapeutic approach seems to be more appropriate. It is well accepted that systemic or intravitreal steroids with or without systemic immunosuppressives should be employed in order to suppress the active inflammation. Anti-VEGF agents should also be administered in order to achieve a better anatomical outcome and visual acuity.
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![Right eye. **a** Color fundus picture: peripapillary scarred area with foveal grayish lesion with subretinal hemorrhage. **b** Venous phase of fluorescein angiogram: lacy subfoveal hyperfluorescence associated with a hypofluorescent rim. **c** OCT scan: foveal hyperreflective material, intraretinal and subretinal fluid. Left eye. **d** Color fundus picture: peripapillary chorioretinal scarring. **e** Venous phase of fluorescein angiogram: normal macula. **f** OCT scan: normal foveal contour.](cop-0006-0408-g01){#F1}

![Right eye. **a** Color fundus picture: large macular scar and extensive chorioretinal scarring around the optic disc. **b** OCT scan: subfoveal fibrosis. Left eye. **c** Color fundus picture: peripapillary chorioretinal scarring with creamy, ill-defined borders and a grayish lesion with subretinal hemorrhage in the papillomacular bundle. **d** Fluorescein angiogram: early venous phase, lacy extrafoveal hyperfluorescence with a hypofluorescent rim and relative hypofluorescence of the peripapillary area. **e** Fluorescein angiogram: venous phase. Composite picture showing the increased hyperfluorescence related to the active disease and coexistent CNV. **f** OCT scan: hyperreflective material with intraretinal and subretinal fluid in the papillomacular bundle.](cop-0006-0408-g02){#F2}

![Left eye. **a** Color fundus picture: chorioretinal scarring around the optic disc with normal-looking fovea. **b** OCT scan: normal foveal contour with a residual scar in the papillomacular bundle.](cop-0006-0408-g03){#F3}
